SUMMARY OF QUALIFICATIONS
Over 25 years of experience in mycology, microbiology, genetics and chemistry. Co-inventor of two patents, recipient of a NIH grant, and a co-author on more than 40 publications and over 40 proceedings. He serves on the National Board of Directors of the American IAQ Council, the Advisory Board of the Indoor Environmental Standards Organization, and the International Advisory Board for the Hong Kong IAQ Society. He is a certified indoor air quality professional (CIAQP), administered through the American Indoor Air Quality Council.

EXPERIENCE

September, 2003 – present: Senior Scientist, Clark Seif Clark, Inc. Duties includes serving as a technical resource for the company, internal and external training in IAQ and microbiology, coordinating IAQ investigations and reporting, expert witnessing, and serving as an official company representative to trade organizations.

2000 – September, 2003: Vice President of Research & Development, directed all research and development projects for the company. Projects included the use of genetic testing via real-time PCR, aerosol testing, and mycotoxins. His responsibilities also included education, representing the company in official capacities, and serving as the liaison officer for BTOX (biosafety level 4 laboratory for bioterrorism) to governmental agencies.

1998 to 2000: Vice President, Northwest Operations, Aerotech Environmental, consulting arm of Aerotech Laboratories. Established the Redmond office in 1998, conducted over 90 IAQ investigations in the Puget Sound area, and organized and directed the Washington Chapter of the American Indoor Air Quality Council.

1996 to 1998: Vice-President, Mycogenesis. Managed multiple projects on antifungal pharmaceuticals and was instrumental in developing the company from its' initial evolution out of EcoPharm. Same responsibilities as outlined for EcoPharm.

1994 to 1996: Senior Scientist and Manager, EcoPharm. Set up company from its founding, supervising both technical and . Involved in natural product development, primarily in discovery of new antifungal compounds from fungi. Retained position as an Research Associate Professor, Department of Plant Pathology, Montana State University. The work resulted in a patent and publications following the isolation, identification, cultivation, and screening cultural byproducts of over 600 fungal isolates from plants.

1990 to 1994: Research Associate Professor (1992-1994), Department of Plant Pathology, Montana State University. Research Assistant Professor (1990-1992), Research Associate (1990-1992). Responsible for development of fungal mutants as biological control agents of weeds and drug plants (a USDA/DEA classified project, since declassified). Organisms and targets included the use of Sclerotinia sclerotiorum, Sclerotium rolfsii, Rhizoctonia solani and Fusarium oxysporum as broad-leaf weed control agents for dandelion, Canada thistle, leafy spurge, coca plants, heroin poppy, and marijuana,

1987 to 1990: Research Scientist, Mycogen Corporation. Responsible for genetic improvement, formulation and application of fungi for biological control of weeds using conventional mutagenesis and selection. Organisms and target weeds included: Alternaria cassiae for control of sicklepod, Fusarium lateritium for control of velvetleaf, Colletotrichum truncatum for control of hemp sesbania, and Xanthomonas campestris for control of annual bluegrass.


EDUCATION
1983: Ph.D. Plant Pathology, Montana State University, Bozeman, MT, GPA 3.6.
1978: M.S. Biology (Microbiology), New Mexico State University, Las Cruces, NM, GPA 3.8.
1976: B.S. Biology (Microbiology), New Mexico State University, Las Cruces, NM, GPA 3.7.

RECENT PUBLICATIONS 

2004. Risk Assessment of Fungal Bioaerosols in Indoor Environments: Current Paradigms and Evolving Concepts. In E. Johanning (ed.), 5th International Bioaersosol Conference on Bioaersols, Fungi, Bacteria, Mycotoxins and Human Health, Saratoga Springs, NY, In press.
2003. Understanding Mycotoxin Testing and Interpretation. IAQ News, 65 (5).
2003. Industrial Hygiene Sampling. In M. J. Boss and D. W. Day (ed.), Biological Risk Engineering Handbook, Infection Control and Decontamination. Lewis Publishers, Boca Raton, FL., pp. 39-70. 
2003. Biological Sampling and Lab Interpretations. In M. J. Boss and D. W. Day (ed.), Biological Risk Engineering Handbook, Infection Control and Decontamination. Lewis Publishers, Boca Raton, FL., pp. 71-96. 
2003. Toxicology. In M. J. Boss and D. W. Day (ed.), Biological Risk Engineering Handbook, Infection Control and Decontamination. Lewis Publishers, Boca Raton, FL., pp. 97-110. 
2003. Risk Assessment. In M. J. Boss and D. W. Day (ed.), Biological Risk Engineering Handbook, Infection Control and Decontamination. Lewis Publishers, Boca Raton, FL., pp. 111-134.
2003. Understanding mycotoxin testing and interpretation: while the science regarding mold exposures is uncertain, the need to protect human health is not. Occupational Hazards, May, 2003.
2002. The Nature of Mycotoxins: Indentification, Dissemination and Impact on Human Health. COLUMNS – Mold 1(11):2-3, 55-57.
2002. Sampling for Mycotoxins. Mold Reporter 2 (3).
2001. New Instrumental Technologies for Bioaerosol Detection and Quantification. INvironment vol. 7 no. 12
2001. Evolving PCR-Based Technologies for Bioaerosol Detection and Quantification. INvironment vol. 7 no. 10.
2001. Molds and Mycotoxins in Indoor Environments: Health Effects, Testing Strategies, Data Interpretation and Risk Assessment. The Monitor, Fall, 2001. American Society of Safety Engineers, Des Plaines, IL.
2001. Application of a Novel Risk Assessment Model to Evaluate Exposure to Molds and Mycotoxins in Indoor Environments. Second NSF International Conference on Indoor Air Health Proceedings, NSF International, Ann Arbor, MI.
2001. Guidelines can Protect Your Firm from Mold-Contamination Headaches. HPAC Engineering, January 2001.
2000. The Potential Health Risk Posed by Endotoxins in Indoor Environments. EH&S Solutions 1(5):18. Environmental Information Association.
2000. A Risk Assessment Model for Mycotoxin-Producing Molds on Human Health in Indoor Environments. EH&S Solutions 1(4):1-4. Environmental Information Association.
2000. A Risk Assessment Model for the Evaluation of Fungal Exposure in Indoor Environments. In W. J. deKoe (ed.), Mycotoxins and Phycotoxins in Perspective at the Turn of the Millennium. International Union of Pure and Applied Chemistry, Wageningen, The Netherlands pp. 123-131.
2000. Application of a Non-Damaging Method to Assess Mold in Spatial Cavities of Buildings. Proceedings of the AWMA 2000 Annual Conference and Exhibition, Salt Lake City, June, 2000. Air and Waste Management Association.
2000. Potential Health Risk of Endotoxins Indoors. INvironment vol 6 No. 8.
1999. Health Effects of Fungi. EH&S Solutions 1 (1):26. Environmental Information Association.
1999. Air-O-Cell Cassettes, Do They Stack-up for Indoor Air Quality Investigations. EH&S Solutions 1: 26. Environmental Information Association.
1999. The Hidden Enemy? EH&S Solutions 1:25. Environmental Information Association.
1999. Cryptocandin, a potent antimycotic from the endophytic fungus Cryptosporiopsis quercina. Microbiology 145:1919-1926.
1998. Ecomycins, Unique Antimycotics from Pseudomonas viridiflava. Journal of Applied Microbiology 84, 937-944.

PRESENTATIONS: 40

PATENTS
U. S. Patent 5,538,890. Self-delimiting Fungal Mutants, Bioherbicidal Compositions Thereof, Method of Preparing Thereof and Method Using Thereof for Weed Control.
U. S. Patent 6,103,875. Antifungal Compounds from Pseudomonas viridiflava.

PROFESSIONAL AFFILIATIONS
American Industrial Hygiene Association
American Conference of Governmental Industrial Hygienists
American Society for Microbiology
National Board of Directors, American Indoor Air Quality Council
Advisory Board, Indoor Environmental Standards Organization
International Advisory Board, Hong Kong Indoor Air Quality